P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

Background: We investigated the immunohistochemical expression of p53, MAPK, topoisomerase II alpha(topoII alpha) and Ki67 in ovarian serous carcinomas (OSCs) along with mutational analysisfor KRAS and BRAF. Methods: Eighty one cases of OSCs were reviewed and examined immunohistochemically usingantibodies against p53, MAPK, topoII alpha and Ki67. Staining was evaluated as apercentage of immunopositive cells with cut-off levels at 10% for p53 and topoII alpha, and5% for MAPK. The Ki67 immunoexpression was assessed by means of Olympus ImageAnalysis System as a percentage of immunopositive cells in 1000 tumor cells. KRAS andBRAF mutational analysis was performed on 73 available microdissected samples. Results: Of 81 cases of OSCs 13.6% were of low-grade and 86.4% were of high-grade morphology. Inthe high-grade group there was a significantly higher immunoexpression of p53 (P
Source: Diagnostic Pathology - Category: Pathology Authors: Source Type: research

Related Links:

Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Gra...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study found that over 94% of salpingectomies resulted in complete removal of salpingeal tissue. Of the ovaries with residual salpingeal tissue, there wasn't a difference among surgeon level and surgery type, but the study was not powered to detect this. This study supports the continued clinical practice of prophylactic salpingectomy for ovarian cancer risk reduction. PMID: 31522838 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
cesca Mancini Maria Pia Gentileschi Gian Franco Zannoni Alfredo Pontecorvi Giovanni Scambia Fabiola Moretti Estrogen activity towards cancer-related pathways can impact therapeutic intervention. Recent omics data suggest possible crosstalk between estrogens/gender and MDM4, a key regulator of p53. Since MDM4 can either promote cell transformation or enhance DNA damage-sensitivity, we analysed in vivo impact of estrogens on both MDM4 activities. In Mdm4 transgenic mouse, Mdm4 accelerates the formation of fibrosarcoma and increases tumor sensitivity to cisplatin as well, thus confirming in vivo Mdm4 dual mode o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: The distribution of disease at the time of first recurrence varied with the choice of primary treatment. Compared to patients treated with PDS, patients who underwent NACT-IDS experienced recurrence more often in the same locations as the original disease. PMID: 31521322 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
In conclusion, these malignancies should be considered a single entity during treatment. IMPACT STATEMENT What is already known on this subject? Epithelial ovarian cancer is the second most common gynaecological cancer in women worldwide. There are different histological types including ovarian, tubal and peritoneal carcinomas in which malignant cells form in the tissue covering the ovary or lining the fallopian tube of peritoneum. Recent data have supported the view that these malignancies should be considered a single entity and should be treated the same way. What the results of this study add? In the present study, we ...
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
ConclusionsThis study is the first report of RRSO results in China. In this systematic review, the positive rates of STIC or OCC after RRSO were no more than 3%, which are 200-fold higher than the risk of the general population. The use of a strict SEE-FIM protocol would likely increase positive results.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Abstract BACKGROUND: Numerous studies have investigated the association between hormone receptor expression and clinical outcome in ovarian carcinoma (OC); however, these have largely focussed on serous OCs, with few studies reporting specifically on endometrioid OCs (EnOC). Where analyses have been stratified by histotype, expression has been assessed using the percentage of positive tumor cells, without accounting for nuclear expression intensity. METHODS: Here we assess the expression levels of progesterone receptor (PR), estrogen receptor alpha (ER) and androgen receptor (AR) using histoscore - a nuclear ...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
CONCLUSION: This study provides strong evidence suggesting that extrauterine HGSC arises from the fimbria of the distal fallopian tube. Furthermore, several potential pathways were identified which could be targeted by novel therapies for HGSC. These findings have significant translational relevance for both primary prevention and clinical management of the disease. PMID: 31493898 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Conclusions: This hypothesis generating study suggests that low expression of ARAP1 is an independent prognostic biomarker of shorter RFS in older patients with HGSC receiving first-line platinum-based antineoplastic therapy, which could be used to identify patients who should receive more intensive treatment and closer surveillance. PMID: 31478407 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.
Source: In Vivo - Category: Research Authors: Tags: Experimental Studies Source Type: research
More News: Cancer & Oncology | Carcinoma | Ovarian Cancer | Ovaries | Pathology | Serous Carcinoma | Study